glp-1 triple agonist LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism GLP-1/GIP/Glucagon Triple Receptor Agonist -
Description
Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, et al
Most people arrive with one specific question, then build confidence as new questions come up
This requires carefully designed clinical trials that account for commercial dynamics, as well as pre-launch disease education to prime market understanding regarding where new therapies fit in the treatment paradigm
s.c., subcutaneous injection
Notably, those on placebo experienced weight gain, a rare finding in obesity studies and one that may further underscore amycretins efficacy
Effective Management: Adjusting dietary parameters
